NICOYA年衍药业
/
← All feature readings
Feature articleAbout 6 min read

别只知道补钙!它,才是隐藏的抗癌高手

别只知道补钙!它,才是隐藏的抗癌高手

一、被误解的维生素D:不只是“补钙小能手”

一提到维生素D,绝大多数人第一反应都是:补钙、强骨骼、预防佝偻病。在很多人的认知里,它只是一个守护骨骼的普通营养素。但,你知道吗?这位我们熟悉又常常被低估的“老朋友”,早已被大量前沿研究证实:它不只是钙的搭档,更是一位实力惊人、全程在线的抗癌多面手[1,2]。

维生素D是一种脂溶性激素前体,上世纪二三十年代因佝偻病研究被发现。

  • 人体约80%的维生素D是依靠皮肤接触阳光中的紫外线,以胆固醇为原料自行合成,剩下约20%来自动物源性D3和植物源性D2。

  • 进入人体后,维生素D先在肝脏转化为25(OH)D——体内维生素D的“储存库”,也是判断维生素D是否缺乏的核心指标。随后在肾脏活化成1,25-(OH)2D,也就是真正发挥生物作用的“活性维生素D”。

维生素D的受体遍布全身,深度参与免疫调节、炎症控制,甚至直接干预肿瘤发生发展的全过程[2-4]。

维生素D代谢概览[1]

二、🔍全方位抗癌:维生素D的五大“硬核技能”

维生素D为什么能抗癌?答案藏在它全方位、多层次、全流程的保护机制里。

维生素D的抗癌特性[1]

✅ 强效抗炎,掐灭癌变“温床”[5-8]

慢性炎症是癌症发生的重要诱因,维生素D能抑制多条关键促炎通路,从根源上减少炎症诱发的细胞损伤与突变。

✅ 抗氧化+修复DNA,守住基因防线[9-12]

维生素D能上调抗氧化酶,同时激活p53、BRCA1等DNA修复蛋白,让受损基因及时“纠错”,避免错误不断累积成癌。

✅ 诱导癌细胞凋亡,清除异常细胞[13-15]

维生素D可下调抗凋亡蛋白、上调促凋亡蛋白,让失控生长的异常细胞“主动退场”,不给肿瘤留机会。

✅ 启动自噬清除,清理体内“危险分子”[16-18]

维生素D能把细胞自噬从“存活模式”切换为“清除模式”,精准清除异常增殖细胞。

✅ 抑制增殖、促分化,降低恶性程度[19-22]

阻断癌细胞无限分裂,推动细胞向成熟稳定方向发展,让肿瘤“长不快、恶不起来”。

三、📊科学证据:25(OH)D水平越高,癌症风险越低

多项综述[23,24]覆盖乳腺癌、结直肠癌、肺癌、胰腺癌、前列腺癌五大常见癌症,结论高度一致:体内25(OH)D水平越高,癌症死亡率越低。

  • 著名的VITAL试验二次分析显示[25]:补充维生素D可显著降低晚期癌症发病率,在体重正常人群中,转移性/致死性癌症风险降低可达38%。

  • 另一项覆盖41万余人的英国生物样本库研究证实[26]:维生素D缺乏与总体癌症、胃癌、结直肠癌、肺癌、前列腺癌死亡率升高显著相关,补充维生素D能明显降低肺癌及总体癌症死亡风险。

四、🎯四大高发癌:维生素D的保护力有多强?

  1. 乳腺癌:尤其保护高危女性[27-30]25(OH)D缺乏者患病风险显著升高,高水平25(OH)D则有明显保护作用,尤其对绝经前女性更友好。更值得警惕的是:25(OH)D水平偏低,与三阴性乳腺癌风险关联极强。新确诊患者中,25(OH)D不足的比例远高于健康人群。

  2. 结直肠癌:证据最充分[31-33]血清25(OH)D每升高10ng/mL,结直肠癌风险呈线性下降,最高水平组较最低组风险降低33%。25(OH)D浓度达50ng/mL时,结直肠癌风险可降低约60%。

  3. 肺癌:降低发病,改善生存[34-36]维生素D摄入与更低发病率相关,还能显著改善总生存期与无复发生存期。25(OH)D每升高10nmol/L,肺癌风险降低5%。

  4. 胰腺癌:改善预后的“希望指标”[37,38]研究显示,较高的25(OH)D水平与更低的胰腺癌死亡率相关,有可能作为晚期胰腺癌的潜在预后标志物。

五、✅简单三步,科学补足25(OH)D水平[2]

1. 适度晒太阳 (最经济有效)

我国多数地区在初夏至秋末季节,于上午10点至下午3点,裸露四肢日晒15-30min,每周2-3次即可。

2. 饮食补充

多脂野生海鱼、晒干的蘑菇、动物肝脏、蛋黄、 瘦肉、牛奶、鱼肝油、乳酪、坚果等。

3. 合理选择补充制剂

日常食物中的维生素D含量有限,难以满足人体所需,当日晒不足时,建议给予维生素D补充剂进行弥补。

六、高效补D:骨化二醇缓释胶囊(Extended-release calcifediol, ERC)

相比营养性维生素D,骨化二醇能更快、更稳提升25(OH)D水平,尤其适合肝功能损伤,先天性肝脏25羟化酶异常,维生素D3吸收不良及肥胖患者维生素D的缺乏[39]。

骨化二醇缓释胶囊(ERC)已获美国食品药品监督管理局批准,用于治疗成人慢性肾脏病3-4期继发性甲状旁腺功能亢进症(SHPT)和维生素D缺乏。通过缓慢释放骨化二醇,不会明显干扰钙磷稳态。ERC已被证实能安全高效纠正维生素D不足,为广大维生素D不足和缺乏的患者提供了新的治疗选择[40]。

七、写在最后:它不是神药,却是高性价比的守护

必须清醒认识:维生素D不是抗癌神药,不能替代筛查、诊断与正规治疗。但它是一种低成本、易普及、覆盖广的防癌营养素。它藏在阳光里,藏在日常饮食中,以温和而持续的力量,为我们筑起一道看不见的抗癌防线。健康往往藏在细节里,保持充足的25(OH)D水平,就是用最简单的方式,给自己一份长久、稳定、靠谱的健康守护。

References

Sang-Min Jeon, Eun-Ae Shin. Exploring vitamin D metabolism and function in cancer. Exp Mol Med. 2018; 50(4): 1-14.

中华医学会骨质疏松和骨矿盐疾病分会. 维生素D及其类似物的临床应用共识(2025版). 中华骨质疏松和骨矿盐疾病杂志. 2025; 18(5): 497-517.

Andrea Giustina, John P Bilezikian, Robert A Adler, et al. Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows. Endocr Rev. 2024; 45(5): 625-654.

J Wesley Pike, Sylvia Christakos. Biology and Mechanisms of Action of the Vitamin D Hormone. Endocrinol Metab Clin North Am. 2017; 46(4): 815-843.

Alberto Mantovani, Paola Allavena, Antonio Sica, et al. Cancer-related inflammation. Nature. 2008; 454(7203): 436-444.

Larisa Nonn, Lihong Peng, David Feldman, et al. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res. 2006; 66(8): 4516-4524.

Yong Zhang, Donald Y M Leung, Brittany N Richers, et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol. 2012; 188(5): 2127-2135.

Qingsong Wang, Yuhu He, Yujun Shen, et al. Vitamin D inhibits COX-2 expression and inflammatory response by targeting thioesterase superfamily member 4. J Biol Chem. 2014; 289(17): 11681-11694.

Visalini Nair-Shalliker, Bruce K Armstrong, Michael Fenech. Does vitamin D protect against DNA damage? Mutat Res. 2012; 733(1-2): 50-57.

Veronika Fedirko, Roberd M Bostick, Qi Long, et al. Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2010; 19(1): 280-291.

Srilatha Swami, Nalini Raghavachari, Uwe R Muller, et al. Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res Treat. 2003; 80(1): 49-62.

Susana Gonzalo. Novel roles of 1α,25(OH)2D3 on DNA repair provide new strategies for breast cancer treatment. J Steroid Biochem Mol Biol. 2014: 144 Pt A: 59-64.

G D Díaz, C Paraskeva, M G Thomas, et al. Apoptosisis induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res. 2000; 60(8): 2304-2312.

Lina Pan, Ammar F Matloob, Juan Du, et al. Vitamin D stimulates apoptosis in gastric cancer cells in synergy with trichostatin A /sodium butyrate-induced and 5-aza-2'-deoxycytidine-induced PTEN upregulation. FEBS J. 2010; 277(4): 989-999.

Héctor G Pálmer, Marta Sánchez-Carbayo, Paloma Ordóñez-Morán, et al. Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. Cancer Res. 2003; 63(22): 7799-7806.

Khushboo Sharma, Rachel W Goehe, Xu Di, et al. A novel cytostatic form of autophagy in sensitization of non-small cell lung cancer cells to radiation by vitamin D and the vitamin D analog, EB 1089. Autophagy. 2014; 10(12): 2346-2361.

M Høyer-Hansen, L Bastholm, I S Mathiasen, et al. Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death. Cell Death Differ. 2005; 12(10): 1297-1309.

Thomas S Lisse, Ting Liu, Martin Irmler, et al. Gene targeting by the vitamin D response element binding protein reveals a role for vitamin D in osteoblast mTOR signaling. FASEB J. 2011; 25(3): 937-947.

Sam Samuel, Michael D Sitrin. Vitamin D's role in cell proliferation and differentiation. Nutr Rev. 2008; 66(10 Suppl 2): S116-1124.

L Yang, J Yang, S Venkateswarlu, et al. Autocrine TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells. J Cell Physiol. 2001; 188(3): 383-393.

Anping Chen, Bernard H Davis, Michael D Sitrin, et al. Transforming growth factor-beta 1 signaling contributes to Caco-2 cell growth inhibition induced by 1,25(OH)(2)D(3). Am J Physiol Gastrointest Liver Physiol. 2002; 283(4): G864-8674.

Ravi Kasiappan, Zheng Shen, Anfernee K-W Tse, et al. 1,25-Dihydroxyvitamin D3 suppresses telomerase expression and human cancer growth through microRNA-498. J Biol Chem. 2012; 287(49): 41297-41309.

Matthias Schömann-Finck, Jörg Reichrath. Umbrella Review on the Relationship between Vitamin D Levels and Cancer. Nutrients. 2024; 16(16): 2720.

Matthias Schömann-Finck, Thomas Vogt, Jörg Reichrath. Umbrella Review on the Relationship Between Vitamin D Intake and Cancer. Anticancer Res. 2025; 45(3): 855-864.

Paulette D Chandler, Wendy Y Chen, Oluremi N Ajala, et al. Effect of Vitamin D3 Supplements on Development of Advanced Cancer: A Secondary Analysis of the VITAL Randomized Clinical Trial. JAMA Netw Open. 2020; 3(11): e2025850.

Sha Sha, Li-Ju Chen, Hermann Brenner, et al. Associations of 25-hydroxyvitamin D status and vitamin D supplementation use with mortality due to 18 frequent cancer types in the UK Biobank cohort. Eur J Cancer. 2023; 191: 113241.

Sharmin Hossain, May A Beydoun, Hind A Beydoun, et al. Vitamin D and breast cancer: A systematic review and meta-analysis of observational studies. Clin Nutr ESPEN. 2019; 30: 170-184.

Nuria Estébanez, Inés Gómez-Acebo, Camilo Palazuelos, et al. Vitamin D exposure and Risk of Breast Cancer: a meta-analysis. Sci Rep. 2018; 8(1): 9039.

Jessica L Tommie, Susan M Pinney, Laurie A Nommsen-Rivers. Serum Vitamin D Status and Breast Cancer Risk by Receptor Status: A Systematic Review. Nutr Cancer. 2018; 70(5): 804-820.

Ioannis A Voutsadakis. Vitamin D baseline levels at diagnosis of breast cancer: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2021; 14(1): 16-26.

Cedric F Garland, Edward D Gorham. Dose-response of serum 25-hydroxyvitamin D in association with risk of colorectal cancer: A meta-analysis. J Steroid Biochem Mol Biol. 2017; 168: 1-8.

Yanlei Ma, Peng Zhang, Feng Wang, et al. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol. 2011; 29(28): 3775-3782.

Pablo Hernández-Alonso, Hatim Boughanem, Silvia Canudas, et al. Circulating vitamin D levels and colorectal cancer risk: A meta-analysis and systematic review of case-control and prospective cohort studies. Crit Rev Food Sci Nutr. 2023; 63(1): 1-17.

Mingxia Qian, Jun Lin, Rongrong Fu, et al. The Role of Vitamin D Intake on the Prognosis and Incidence of Lung Cancer: A Systematic Review and Meta-Analysis. J Nutr Sci Vitaminol (Tokyo). 2021; 67(5): 273-282.

Jian-Da Huang, Chao-Hui Dong, Sheng-Wen Shao, et al. Circulating 25-hydroxyvitamin D level and prognosis of lung cancer patients: A systematic review and meta-analysis. Bull Cancer. 2017; 104(7-8): 675-682.

Guo-Chong Chen, Zeng-Li Zhang, Zhongxiao Wan, et al. Circulating 25-hydroxyvitamin D and risk of lung cancer: a dose-response meta-analysis. Cancer Causes Control. 2015; 26(12): 1719-1728.

Yajing Shen, Junfen Xia, Chuncheng Yi, et al. The association between circulating 25-hydroxyvitamin D and pancreatic cancer: a systematic review and meta-analysis of observational studies. Eur J Nutr. 2024; 63(3): 653-672.

Jing Li, Haiyan Zhang, Hongda Zhu, et al. 25-hydroxyvitamin D concentration is positively associated with overall survival in advanced pancreatic cancer: A systematic review and meta-analysis. Nutr Res. 2023; 117: 73-82.

Roberto Cesareo, Roberto Attanasio, Marco Caputo, et al. Italian Association of Clinical Endocrinologists (AME) and Italian Chapter of the American Association of Clinical Endocrinologists (AACE) Position Statement: Clinical Management of Vitamin D Deficiency in Adults. Nutrients. 2018; 10(5): 546.

Stuart M Sprague, Stephen A Strugnell, Charles W Bishop. Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Expert Rev Endocrinol Metab. 2017; 12(5):289-301.